Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes

被引：0
|
作者：
Slomski, Anita
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2022年 / 328卷 / 09期
关键词：
D O I：
10.1001/jama.2022.14696
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：817 / 817
页数：1
相关论文
共 50 条
  • [21] No increased risk of cardiovascular events with dapagliflozin in elderly patients with type 2 diabetes mellitus, cardiovascular disease and hypertension
    Gause-Nilsson, I.
    Sonesson, C.
    Johansson, P. A.
    Johnsson, E.
    [J]. DIABETOLOGIA, 2015, 58 : S362 - S363
  • [22] Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D)
    Ang, Lynn
    Kidwell, Kelley M.
    Dillon, Brendan
    Reiss, Jacob
    Fang, Fang
    Leone, Virginia
    Mizokami-Stout, Kara
    Pop-Busui, Rodica
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (08)
  • [23] Dapagliflozin and Insulin Resistance in Patients with Type 2 Diabetes
    Katz, Arie
    Yeh, Helen
    [J]. DIABETES, 2015, 64 : A304 - A305
  • [24] Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
    Avgerinos, Ioannis
    Liakos, Aris
    Tsapas, Apostolos
    Bekiari, Eleni
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2549 - 2557
  • [25] Correction of anemia by dapagliflozin in patients with type 2 diabetes
    Stefansson, Bergur V.
    Heerspink, Hiddo J. L.
    Wheeler, David C.
    Sjostrom, C. David
    Greasley, Peter J.
    Sartipy, Peter
    Cain, Valerie
    Correa-Rotter, Ricardo
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2020, 34 (12)
  • [26] Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
    Iijima, Yasuhiro
    Nakayama, Masafumi
    Miwa, Takashi
    Yakou, Fumiyoshi
    Tomiyama, Hirofumi
    Shikuma, Junpei
    Ito, Rokuro
    Tanaka, Akihiko
    Manda, Naoki
    Odawara, Masato
    [J]. INTERNAL MEDICINE, 2023, 62 (05) : 681 - 688
  • [27] Renal effects of dapagliflozin in patients with type 2 diabetes
    Thomas, Merlin C.
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2014, 5 (03) : 53 - 61
  • [28] Phase III study shows benefit of dapagliflozin in treating Type 2 diabetes
    不详
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (06) : 795 - 795
  • [29] Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
    Yandrapalli, Srikanth
    Jolly, George
    Horblitt, Adam
    Sanaani, Abdallah
    Aronow, Wilbert S.
    [J]. POSTGRADUATE MEDICINE, 2017, 129 (08) : 811 - 821
  • [30] Cardiovascular safety of dapagliflozin in type 2 diabetes mellitus (T2DM) patients with various degrees of cardiovascular risk
    Sonesson, C.
    Frederich, R.
    Johansson, P. A.
    Gause-Nilsson, I.
    Langkilde, A. M.
    List, J. F.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 1072 - 1072
12345